RTI Surgical, Inc. (RTIX) to Release Quarterly Earnings on Thursday
RTI Surgical, Inc. (NASDAQ:RTIX) is set to announce its earnings results before the market opens on Thursday, November 2nd. Analysts expect the company to announce earnings of $0.01 per share for the quarter. RTI Surgical has set its FY17 guidance at 0.04-0.08 EPS.
RTI Surgical (NASDAQ:RTIX) last posted its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $72.10 million during the quarter, compared to analysts’ expectations of $70.25 million. RTI Surgical had a positive return on equity of 2.07% and a negative net margin of 6.53%. RTI Surgical’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, analysts expect RTI Surgical to post $0.06 EPS for the current fiscal year and $0.13 EPS for the next fiscal year.
RTI Surgical, Inc. (RTIX) remained flat at $4.60 during mid-day trading on Friday. 176,606 shares of the company traded hands. The firm’s market capitalization is $271.56 million. RTI Surgical, Inc. has a 12-month low of $2.50 and a 12-month high of $6.00. The stock’s 50-day moving average price is $4.63 and its 200-day moving average price is $4.90.
In other news, Director Nicholas J. Valeriani bought 5,500 shares of the business’s stock in a transaction on Monday, August 21st. The stock was purchased at an average cost of $4.70 per share, for a total transaction of $25,850.00. Following the completion of the transaction, the director now directly owns 47,754 shares of the company’s stock, valued at approximately $224,443.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John N. Varela bought 12,000 shares of the business’s stock in a transaction on Friday, August 11th. The stock was purchased at an average price of $4.85 per share, with a total value of $58,200.00. Following the completion of the transaction, the executive vice president now directly owns 47,998 shares of the company’s stock, valued at $232,790.30. The disclosure for this purchase can be found here. Insiders own 4.90% of the company’s stock.
RTIX has been the subject of several analyst reports. Zacks Investment Research downgraded RTI Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. BidaskClub downgraded RTI Surgical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th.
About RTI Surgical
RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.
Receive News & Ratings for RTI Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.